Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031576 | 0.86 | ACHE (0.41) | OPRK1PIK3CDPIK3CGOPRM1 | |
| SCHEMBL4033694 | 0.84 | OPRK1 (0.41) | CNR2OPRK1HRH3 | |
| SCHEMBL4032284 | 0.81 | OPRK1 (0.44) | OPRK1PIK3CDPIK3CGOPRM1 | |
| SCHEMBL4667315 | 0.80 | HRH3 (0.50) | HRH3 | |
| Hydrochloric Acid SCHEMBL4668335 | 0.79 | HRH3 (0.49) | HRH3 | |
| SCHEMBL4666700 | 0.77 | HRH3 (0.56) | HRH3 | |
| Hydrochloric Acid SCHEMBL4668345 | 0.77 | HRH3 (0.55) | HRH3 | |
| SCHEMBL4031218 | 0.74 | NPY2R (0.51) | OPRK1PIK3CDPIK3CGOPRM1 | |
| SCHEMBL4034511 | 0.73 | USP7 (0.45) | OPRK1 | |
| SCHEMBL5211298 | 0.73 | USP30 (0.42) | OPRK1HRH3PIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638631-B2 | Methylene dipiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2009-12-29 | — | — | US | claimed |
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | claimed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | claimed |
| US-7638631-B2 | Methylene dipiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2009-12-29 | — | — | US | disclosed |
| US-7638631-B2 | Methylene dipiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2009-12-29 | — | — | US | disclosed |
| US-7638631-B2 | Methylene dipiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2009-12-29 | — | — | US | disclosed |
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | disclosed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | disclosed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | disclosed |
| EP-1789410-A1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006029906-A1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | DRD2, DRD4, PNMT | CNR2 70/4885OPRK1 88/4885HRH3 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.